European Journal of Cardiovascular Medicine

Generalized Anxiety Disorder (GAD), Panic Disorder (PS), and Major Depression (MD) are frequently comorbid psychiatric conditions that share complex neurobiological and genetic mechanisms . Understanding these interrelationships is crucial to the development of effective therapeutic approaches . GAD , characterized by excessive and persistent worry , can progress to episodes of panic and depression as brain dysfunction deepens. The morphological changes observed in the hippocampus and prefrontal cortex resulting from this progression have direct implications for memory , decision - making and inertial behavior , making it difficult to seek treatment. Genetic predisposition , modulated by environmental influences , also plays a significant role in the manifestation of these disorders, highlighting the need for personalized interventions that consider both neurobiological aspects and contextual factors.

Neurobiology of GAD and Comorbidity with SP and DM

The pathophysiology of GAD involves the complex interaction between neurotransmitters and specific neuronal circuits, located mainly in the limbic system and prefrontal cortex. Hyperactivity of the amygdala, associated with the dorsolateral and ventromedial prefrontal cortex , plays a crucial role in the regulation of fear and anxiety responses . Studies indicate that dysfunction in the hypothalamic -pituitary - adrenal (HPA) axis is frequently observed in patients with GAD, evidencing the direct link between chronic stress and hormonal dysregulation , particularly involving CRH (Corticotropin-Releasing Hormone ) and cortisol (GORMAN et al., 2000; SOUTHWICK et al., 2005).

In Panic Syndrome , marked dysfunction is observed in the periaqueductal gray matter and in the insula , regions that modulate autonomic responses to fear. High noradrenaline activity , mediated by the locus coeruleus, is closely associated with acute panic episodes , contributing to symptoms such as tachycardia, sweating and a feeling of impending doom (CHARNEY, 2003; GORDON and HEN, 2004). In addition , serotonin (5-HT) and dopamine dysfunction may exacerbate vulnerability to panic attacks and depression .

The relationship between GAD and Major Depression can be explained by synaptic plasticity and neurogenesis in the hippocampus. The reduction in serotonin and dopamine levels, associated with the decrease in BDNF ( Brain-Derived Neurotrophic Factor ) , compromises the brain's ability to adapt to chronic stress , resulting in depressive symptoms (DU et al., 2015). Dysfunction in the ventromedial prefrontal cortex and in the rostral region, involved in emotional regulation and reward processing, is particularly significant in the precipitation of depressive states (PRICE and DREVETS, 2010).

Relationship between GAD , Panic Syndrome and Depression : Neurobiological Pathways and Morphological Consequences​

The relationship between Generalized Anxiety Disorder (GAD), Panic Disorder ( PS) , and Major Depression (MD) involves a complex interaction of neurobiological mechanisms that can lead to the concomitant development of these disorders. GAD, often characterized by diffuse and persistent anxiety, can progress to panic episodes and , eventually, to depression, as brain dysfunction becomes more pronounced and widespread. Understanding this pathway is crucial to understanding the morphological consequences that these disorders entail .

Neurobiological Pathway from GAD to Panic and Depression: GAD, when persistent over time, can induce a sensitization of the neural pathways responsible for the stress response, particularly involving the amygdala , hippocampus and prefrontal cortex . Chronic hyperactivity of the amygdala, associated with deficient regulation by the dorsolateral prefrontal córtex , can exacerbate the perception of threats , culminating in panic attacks ( CHARNEY, 2003). These attacks, in turn, can be accompanied by a series of physical symptoms , such as tachycardia, sweating and a feeling of impending doom, although it is important to emphasize that such symptoms are not universal ; patients may experience only some, all or even other less typical symptoms (GORDON and HEN, 2004).

As panic episodes become more frequent, the resilience of the limbic system and prefrontal cortex may be further compromised, increasing vulnerability to developing depression. Progressive reduction of synaptic plasticity in the hippocampus and decreased BDNF levels are critical factors contributing to this transition ( DU et al . , 2015). Depression is a direct consequence of the brain 's inability to adapt to ongoing stress and exaggerated fear responses .

Morphological Consequences: The morphological consequences of this progression from GAD to panic and depression include significant structural and functional changes in the brain. The hippocampus, a region crucial for memory and emotional regulation, may show a reduction in volume due to impaired neurogenesis and neuron loss, an effect widely documented in patients with chronic depression (SHELINE et al., 1999). Furthermore , the prefrontal cortex , particularly its dorsolateral and ventromedial regions , may show cortical thinning, reflecting loss of synaptic connectivity and decreased executive and emotional regulation (PRICE and DREVETS, 2010).

In the case of Panic Syndrome , the periaqueductal gray matter and the insula may undergo functional changes that amplify the autonomic response to stress , perpetuating the cycle of panic attacks . These changes are not only functional , but may also manifest as changes in the density of neurotransmitter receptors, such as serotonin and norepinephrine, in the affected areas (GORDON and HEN, 2004).

Morphological changes in the hippocampus and prefrontal cortex associated with the progression of GAD to panic and depression have a significant impact on memory , decision - making and inertial behavior . The hippocampus , which is essential for declarative and spatial memory , undergoes volume reduction and impaired neurogenesis , compromising the formation of new memories and the retrieval of information , affecting the ability to learn and remember recent events. The dorsolateral and ventromedial prefrontal cortex , in turn, are crucial for decision-making and emotional regulation . Cortical thinning in these regions reduces synaptic connectivity , weakening the ability to assess and plan, resulting in a tendency toward inertia and risk aversion . This impairment is exacerbated by a lack of motivation , which is directly related to decreased dopaminergic activity in these areas , leading to anhedonia , which is the inability to feel pleasure or interest in activities that were previously pleasurable. The combination of these brain dysfunctions results in a preference for avoiding action , keeping the individual in a state of inertia .

At this stage of neurobiological impairment , the individual may choose not to seek professional help, a behavior often driven by dysfunction in regions of the prefrontal cortex that impairs decision-making and fuels inertia. Failure to provide appropriate intervention, especially medications that can restore homeostatic neurotransmitter balance, may allow these anatomical changes, such as reduced hippocampal volume and cortical thinning in the prefrontal cortex, to become permanent . This not only perpetuates symptoms of anxiety, panic , and depression , but also makes recovery even more difficult , creating a vicious cycle of neurobiological dysfunction and cognitive and emotional decline .

The progression from GAD to Panic Disorder and eventually Major Depression reflects a complex network of neurobiological dysfunctions that have profound morphological consequences in the brain . Understanding these changes is critical to implementing therapeutic interventions that can interrupt this cycle before significant structural damage occurs. It is crucial that clinicians recognize the variability of panic symptoms and the long-term consequences of chronic brain dysfunction in order to provide more effective and individualized treatment .

Genetic Predisposition and Environmental Implications​​

Genome - wide association studies (GWAS) have identified genetic variants associated with the risk of concomitant development of GAD, SP, and DM. Polymorphisms in the SLC6A4 gene , which encodes the serotonin transporter, and in the BDNF gene have been consistently associated with an increased vulnerability to these disorders (CASPI et al., 2003; KARG et al., 2011). Furthermore , the COMT gene , involved in dopamine degradation in the prefrontal cortex , has variants that may predispose to cognitive and emotional dysfunction in individuals with these comorbidities (MURPHY et al., 2013).

In addition to genetic factors , the environment plays a critical role in modulating gene expression and triggering these disorders. Although childhood trauma is often implicated in altering epigenetics , stressful events are not the only relevant environmental factors. Children raised in environments with little or no structure, where rules and boundaries are absent or vaguely defined, may develop difficulties in emotional and behavioral regulation , increasing their vulnerability to disorders such as GAD , SP, and MD. The lack of clear rules can impair the development of internal mechanisms of self-control and resilience , essential for managing stress and emotions in adulthood.

Individuals with a genetic predisposition to faster synaptic processing may also be at increased risk for developing these disorders. This trait may be advantageous in contexts of high cognitive demand, but in situations of prolonged stress or when combined with a deficient emotional and behavioral structure, it may lead to hyper-reactivity of the nervous system. This hyper-reactivity may amplify anxiety responses and make emotional regulation difficult, contributing to the manifestation of GAD , panic , and depression . Epigenetic modifications resulting from these environmental and genetic factors can result in lasting changes in brain morphology, such as reduced hippocampal volume and decreased functional connectivity between the prefrontal cortex and the amygdala , perpetuating states of anxiety and depression ( FRODL et al., 2010) .

The Role of Family Support in the Context of Panic Attacks and Depression : Decision Making Impaired by Brain Dysfunction

Family support plays a crucial role in the management of anxiety and depressive disorders . However, the very nature of these disorders can make it difficult to seek professional help, leading to the postponement of appropriate interventions . Panic attacks and major depression significantly affect individuals' decision - making capacity , often resulting in inertia and resistance to seeking treatment (AMIR et al., 2000 ) .

Impact of Brain Dysfunction on Decision Making : The brain regions involved in decision making , particularly the dorsolateral prefrontal cortex and ventromedial prefrontal cortex , are severely affected in conditions of depression and chronic anxiety . Dysfunction in these areas impairs the individual 's ability to evaluate risks and benefits , resulting in excessive risk aversion or an inability to act (KOENIG et al., 2004). An overactive amygdala , often associated with heightened fear responses, can dominate the decision - making process , suppressing the rational involvement of the prefrontal cortex ( BRUNNER et al . , 2014).

In depression , there is a reduction in dopaminergic and serotoninergic activity , which decreases motivation and pleasure, essential components for goal-oriented action (TESSON et al., 2013). The difficulty in experiencing pleasure, known as anhedonia, combined with the lack of energy, contributes to inertia and procrastination , making it difficult to decide to seek professional help. This inertia is often misinterpreted by family members as a lack of need, desire, or apathy, sometimes the patient trying to convince family members that everything is fine , when in fact it reflects a deep neurobiological dysfunction ( PRICE and DREVETS , 2010).

The Role of the Family and the Need for Intervention :Given that brain dysfunction impairs decision -making ability , the role of the family becomes even more critical . Family members can be essential in breaking the cycle of inertia by offering support and actively encouraging the search for treatment. However, it is essential that the family understand the nature of the brain dysfunction involved, avoiding simplistic interpretations of the patient's behavior.

An overactive amygdala can generate exaggerated fear responses to the idea of change or intervention , which can be interpreted as resistance to treatment (KOENIG et al., 2004). The prefrontal cortex , which would normally rationally evaluate treatment options, is compromised , leaving the patient trapped in a state of indecision and fear. Therefore, family intervention must be conducted with sensitivity and understanding , offering emotional support while facilitating access to professional care.

Therapeutic Approaches for GAD , Panic Disorder and Depression

Effective treatment for Generalized Anxiety Disorder (GAD), Panic Disorder ( PS), and Major Depression (MD) usually involves a combination of pharmacological and psychotherapeutic interventions aimed at restoring neurochemical balance and promoting emotional resilience . Each of these disorders, although interrelated, requires specific approaches at different stages of treatment.

Pharmacological Treatment : For GAD , selective serotonin reuptake inhibitors (SSRIs) , such as sertraline and escitalopram, are often the first line of treatment. These medications work by increasing the availability of serotonin in the brain , which helps regulate mood and anxiety (BALDWIN et al., 2011). In cases of treatment-resistant GAD, serotonin and noradrenaline reuptake inhibitors (SNRIs) may be considered , such as venlafaxine, which in addition to acting on serotonin, also modulates noradrenaline, contributing to a therapeutic response. It is more robust (STEIN et al., 2010).

In Panic Syndrome , in addition to SSRIs, benzodiazepines such as alprazolam or clonazepam can be used for rapid relief of acute symptoms. However, due to the risk of dependence , these medications are indicated only for short-term use or in combination with SSRIs until the latter reach their full therapeutic effect (OTTO et al., 2001). In cases where panic symptoms are refractory , medications such as clomipramine, a tricyclic antidepressant that has shown efficacy in the treatment of panic disorders, may be prescribed ( BALLENGER , 2000 ) .

For Major Depression , SSRIs remain a first-line choice, but in more severe or resistant cases, atypical antidepressants , such as mirtazapine or bupropion, may be indicated. Mirtazapine, for example, in addition to its action on serotonin receptors, also antagonizes histamine receptors, which may be beneficial for patients with insomnia associated with depression ( Thase et al., 2009). In situations of severe depression with risk of suicide , the introduction of an atypical antipsychotic , such as quetiapine, in combination with an antidepressant, may be necessary ( Nelson et al., 2015).

Psychotherapeutic Treatment : In parallel with drug treatment, psychotherapy plays an essential role in the recovery of these disorders. Cognitive-Behavioral Therapy (CBT) is particularly effective in the treatment of GAD and SP, helping patients to identify and modify dysfunctional thought patterns that perpetuate anxiety and panic (HOFMANN et al., 2012). In the treatment of depression , CBT can be combined with Interpersonal Therapy (IPT) to address both the cognitive and relational aspects of the illness , improving coping skills and reducing the risk of relapse ( CUIJPERS et al., 2011).

Treatment choice should be individualized, taking into account the severity of symptoms, the presence of comorbidities, and previous response to treatments. In all cases, continuous monitoring is crucial to adjust interventions as necessary , aiming for complete remission of symptoms and prevention of relapses.

Morphological changes associated with GAD, SP, and MD can be permanent, especially if they occur at critical stages of brain development. Reduced hippocampal volume, often observed in individuals with chronic depression , is an example of how chronic stress can result in lasting structural changes ( SHELINE et al., 1999). Furthermore , loss of synaptic plasticity and reduced neurogenesis in the hippocampus and other brain regions , such as the prefrontal cortex , may exacerbate vulnerability to stress and depression ( DU et al., 2015).

Dysfunction in neuronal circuits, such as impaired connectivity between the prefrontal cortex and the amygdala , can perpetuate inappropriate responses to stress, resulting in a cycle of exacerbation of symptoms of anxiety and depression ( TREADWAY et al., 2012). These changes are accompanied by neurochemical changes , such as a decrease in serotoninergic and dopaminergic neurotransmission , which can reinforce negative mood states and anxiety .

Final Considerations​

The interconnection between GAD, SP and MD reflects an overlap of neurobiological dysfunctions that have profound consequences on brain structure and function . The treatment of these disorders should be approached holistically , integrating pharmacological and psychotherapeutic interventions adjusted to individual needs . Early identification and appropriate intervention are essential to prevent morphological changes from becoming permanent, worsening the clinical picture . A detailed understanding of the neurobiological and epigenetic underpinnings of these disorders may guide the development of new therapeutic strategies that are potentially more effective in reversing associated dysfunctions and promoting full and sustained recovery . Panic attacks and major depression profoundly affect decision -making capacity , leading many patients to inertia and delay in seeking professional help. Dysfunction in key areas of the brain , such as the prefrontal cortex and amygdala , prevents rational decision - making , highlighting the importance of family support in encouraging treatment. Understanding the limitations imposed by brain dysfunction is crucial for family intervention to be effective, preventing the patient from remaining in a state of inertia and perpetuation of suffering

1. AMIR, N. et al. Predictors of emotional response to a panic challenge in a community sample of individuals with panic attacks. Journal of Affective Disorders, v. 61, n. 1, p. 91-96, 2000.
2. BALDWIN, D. S. et al. Evidence-based pharmacological treatment of generalized anxiety disorder. The International Journal of Neuropsychopharmacology, v. 14, n. 5, p. 697-710, 2011.
3. BALLENGER, J. C. Panic disorder and agoraphobia. In: SADDOCK, B. J.; RUIZ, P.; SADDOCK, V. A. (Eds.). Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2000. p. 1557-1568.
4. BECK, A. T.; EMERY, G.; GREENBERG, R. L. Anxiety Disorders and Phobias: A Cognitive Perspective. 15. ed. New York: Basic Books, 2016.
5. BRUNNER, R. et al. Amgydala and orbitofrontal reactivity to emotional faces in adolescents with severe mood dysregulation or major depressive disorder. Neuropsychopharmacology, v. 39, n. 2, p. 352-360, 2014.
6. CASPI, A. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, v. 301, p. 386–389, 2003.
7. CHARNEY, D. S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatrica Scandinavica Supplementum, v. 108, p. 38–50, 2003.
8. CUIJPERS, P. et al. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. Journal of Clinical Psychiatry, v. 71, n. 2, p. 205-218, 2011.
9. DU, J. et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proceedings of the National Academy of Sciences, v. 112, n. 36, p. 10792–10797, 2015.
10. FRODL, T. et al. Childhood stress, serotonin transporter gene and brain structures in major depression. Neuropsychopharmacology, v. 35, n. 6, p. 1383-1390, 2010.
11. GORDON, J. A.; HEN, R. Genetic approaches to the study of anxiety. Annual Review of Neuroscience, v. 27, p. 193-222, 2004.
12. GORMAN, J. M. et al. Fear and anxiety: the benefits of translational research. American Journal of Psychiatry, v. 157, n. 6, p. 858-866, 2000.
13. HOFMANN, S. G. et al. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognitive Therapy and Research, v. 36, n. 5, p. 427-440, 2012.
14. KARG, K. et al. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Archives of General Psychiatry, v. 68, n. 5, p. 444-454, 2011.
15. KOENIG, J. I.; COOKE, B. M.; CREW, R. C. Stress, steroids, and depression: A clinical perspective. Trends in Neurosciences, v. 27, n. 12, p. 636-642, 2004.

16. MCGOWAN, P. O. et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neuroscience, v. 12, n. 3, p. 342-348, 2009.
17. MURPHY, D. L. et al. Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Journal of Affective Disorders, v. 148, n. 2-3, p. 99-111, 2013.
18. NELSON, J. C. et al. A systematic review and meta-analysis of the efficacy of atypical antipsychotics in major depressive disorder. Journal of Clinical Psychiatry, v. 76, n. 4, p. 524-531, 2015.
19. OTTO, M. W. et al. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behaviour Research and Therapy, v. 38, n. 8, p. 881-889, 2000.
20. PRICE, J. L.; DREVETS, W. C. Neurocircuitry of mood disorders. Neuropsychopharmacology, v. 35, n. 1, p. 192–216, 2010.
21. RESSLER, K. J.; NEMEROFF, C. B. The Neurobiology of Post-Traumatic Stress Disorder. New York: Oxford University Press, 2020.
22. SHELINE, Y. I. et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biological Psychiatry, v. 50, n. 9, p. 651-658, 1999.
23. SOUTHWICK, S. M. et al. Neurobiological and neurocognitive alterations in PTSD: A focus on resilience and vulnerability. Psychiatry Research, v. 131, n. 3, p. 263-274, 2005.
24. STEIN, D. J. et al. Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry, v. 71, n. 11, p. 1419-1425, 2010.
25. TESSON, F. et al. Dopaminergic system dysregulation and vulnerability to depression. Neuroscience, v. 247, p. 299-319, 2013.
26. THASE, M. E. et al. Comparative efficacy of newer and older antidepressants: a meta-analysis. Acta Psychiatrica Scandinavica, v. 121, n. 2, p. 162-173, 2009.